Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides*
Arie Admon
,
Eilon Barnea and
Tamar Ziv
From the Department of Biology, Technion, Haifa 32000, Israel
 |
ABSTRACT
|
---|
The major histocompatibility complex (MHC) peptide repertoire of cancer cells serves both as a source for new tumor antigens for development of cancer immunotherapy and as a rich information resource about the protein content of the cancer cells (their proteome). Thousands of different MHC peptides are normally displayed by each cell, where most of them are derived from different proteins and thus represent most of the cellular proteome. However, in contrast to standard proteomics, which surveys the cellular protein contents, analyses of the MHC peptide repertoire correspond more to the rapidly degrading proteins in the cells (i.e. the transient proteome). MHC peptides can be efficiently purified by affinity chromatography from membranal MHC molecules, or preferably following transfection of vectors for expression of recombinant soluble MHC molecules. The purified peptides are resolved and analyzed by capillary high-pressure liquid chromatography-electrospray ionization-tandem mass spectrometry, and the data are deciphered with new software tools enabling the creation of large databanks of MHC peptides displayed by different cell types and by different MHC haplotypes. These lists of identified MHC peptides can now be used for searching new tumor antigens, and for identification of proteins whose rapid degradation is significant to cancer progression and metastasis. These lists can also be used for identification of new proteins of yet unknown function that are not detected by standard proteomics approaches. This review focuses on the presentation, identification and analysis of MHC peptides significant for cancer immunotherapy. It is also concerned with the aspects of human proteomics observed through large-scale analyses of MHC peptides.
 |
LOOKING AT THE PROTEOME FROM THE POINT OF VIEW OF THE IMMUNE SYSTEM
|
---|
The proteome resembles in many ways a Japanese rock garden; looking at it from different viewpoints reveals its different intricacies. One of the many focuses of proteomics is the search for the changes in the patterns of protein expressions associated with the onset of diseases. Searching for such changes is not merely a matter of scientific curiosity but also a means to develop new drugs and treatments modalities for these ailments. The immune system, likewise, attempts to identify these minute changes in the cellular proteome, while looking for the presence of telltale amounts of abnormal or foreign proteins. These serve as the alarm signals, indicating to the immune system the onset of infections and diseases. One of the ways the immune system attempts to eliminate pathogens is by killing infected cells with its cellular arm, thus preventing further spread of disease.
The major histocompatibility complex (MHC)1 molecules are peptide shuttles, transporting peptides from the cytoplasm to the cell surface. MHC class I molecules are products of the MHC-A, -B, and -C genes expressed in most of the nucleated cell types in the body (in humans the MHC molecules are called human leukocytes antigens, HLA). MHC class I molecules are loaded in the endoplasmic reticulum (ER) with peptides derived from proteasomal proteolysis of both normal and pathogenic proteins, most of which are 810 amino acids long. The MHC molecules are then shuttled to the cell surface with their peptide cargo, which are presented for scrutiny by CD8+ T lymphocytes through their T cell receptor (TCR). To prevent autoimmunity, high-affinity T cells specific for MHC molecules presenting "self" peptides are normally eliminated in the thymus by the end of the embryonic stage (central tolerance). Therefore, in healthy individuals the majority of the T cell population is thought to be composed of those T cells recognizing at high-affinity "non-self" peptides. Tight and long-lasting binding of T cells to cells presenting MHC molecules with non-self peptides elicits a cytotoxic response that results in the killing of the infected cells and prevents further spread of the disease (15). The body is left with T cells capable of binding to self epitopes at low affinity, and these are down-regulated by peripheral tolerance mechanisms including "ignorance" in order to prevent autoimmunity (6). Vaccination in the presence of strong adjuvant helps to overcome tolerance by stimulating "anti-self" T cells through presentation of epitopes on activated dendritic cells (reviewed in Ref. 7).
Thus, immune recognition is tightly connected to the cellular schemes of protein degradation. It is also affected by the processing of the degradation products into MHC peptides and by the properties of individual MHC molecules as peptide receptors and mediators of immune recognition. Protein degradation thus serves not only as the "end-of-life" of proteins, aimed at recycling of their amino acids into new proteins, but also as a means of communicating to the immune system the health state of the cells. It puts MHC peptides at the crossroad of proteomics and immunology, where the MHC peptides can serve as indicators for aspects of the cellular proteomes relevant to cancer, autoimmune, and viral diseases. This knowledge can be exploited for developments of new therapeutics for these diseases and also to ascertain which proteins are expressed and degraded in the cells. The large-scale analyses of MHC peptides thus offer a novel viewpoint into the parts of the cellular proteome often overlooked by other proteomics approaches. This review focuses on the aspect of human proteomics that can be observed by large-scale analyses of MHC peptides and their impact on cancer immunotherapy.
 |
TUMOR IMMUNOLOGY
|
---|
Research on tumor immunology aims on one hand to find ways to exploit the capacity of the immune system to kill tumor cells (immunotherapy) and on the other hand to identify new tumor markers for diagnostics, prognostics, or as targeting molecules. The immune system can be induced to reject cancer cells by augmenting the existing weak anti-tumor immune response through therapeutic vaccination with tumor antigens. Preferred antigens for immunotherapy are tumor-specific antigens (TSA), which are proteins and peptides essentially absent from all normal cells in the body (reviewed in Refs. 818). The most desired TSA for immunotherapy are mutated proteins, preferably those needed to maintain the transformed state of cancer cells. Other useful TSA are embryonic proteins, which are expressed as a result of the loss of cellular control prevalent in cancer cells (19). Tumor-associated antigens (TAA) are proteins that are not unique to cancer cells but are expressed to a larger extent in tumor relative to normal cells, some of which are potentially useful for immunotherapy. TAA include cancer testis antigens, which are proteins normally expressed in immune-privileged tissues (such as testis and placenta) and differentiation antigens, which are normally expressed in nonessential tissues (such as prostate, ovaries, and melanocytes). Both cancer testis antigens and differentiation antigens were extensively tested for their immunotherapeutic potential, and some of them have been shown to induce powerful response with measurable benefit to the patients (20).
In cancer patients, spontaneous anti-tumor immune response are apparently too weak to cause spontaneous rejection of the tumors; otherwise cancer would not occur (13). Therapeutic vaccination with specific tumor antigens was attempted in many clinical trials, resulting in partial response in some of the treated patients, while a complete tumor regression was observed in only a small fraction of the patients. It was suggested that the preferred time for immunotherapy is at the minimal residual disease stage, because micro-metastases are expected to be more responsive than large tumors with their immune suppressing microenvironment (21, 22, reviewed in Ref. 23).
 |
SEARCHING FOR TAAS BY PROTEOMICS
|
---|
The majority of the known TAAs were identified by different immunological, genetic, and proteomic methods. Proteomics was used for comparisons between tumor and normal cells using two-dimensional PAGE, liquid chromatography (LC)-LC-mass spectrometry (MS), and surface enhanced laser desorption/ionization (SELDI)-MS (2426, reviewed in Ref. 27). Serological identification of antigens by recombinant expression cloning (SEREX) and serological proteomics are more recent approaches for identification of proteins against which antibodies are present in the serum of people inflicted with cancer. Some of the TAAs identified this way were selected for further immunologic tests (2830, reviewed in Refs. 24, 31, and 32). Tumor antigens were also identified by related genetic and reverse immunology approaches based on searching for genes overexpressed in cancer cells using serial analysis of gene expression (SAGE) or DNA micro-arrays data (3335) and then further testing them for their immunogenic properties (36, 37).
Identification of useful new tumor antigens is limited by a number of obstacles. First, "the problem of the needle in a haystack": TAAs are often minor components of the cells, hidden among other abundant proteins, which makes their identification a demanding task (38). Second, there is no simple way to ascertain the uniqueness of TSA expression in tumor cells, raising the concerns that their administration might cause autoimmune diseases inadvertently. SAGE or micro-arrays data of all human tissues were used for screening for tumors-specific expression. However, it is possible that the concern of causing autoimmunity was not justified in most cases. Vaccination with antigens that are expressed also in normal tissues, such as mucin, p53, and even total tumor mRNA or unfractionated protein or peptide extracts, did not cause the feared intolerable autoimmunity in most (3941) but not in all cases (42, 43). Third, the safety and immunogenic potential of each tumor antigen identified needs to be evaluated in human trials, because laboratory animals are insufficient models in this regard. Normal human proteins are by definition non-self in mice and therefore every identified TAA needs to be tested for its immunogenic potential and efficacy with humans. However, human trials with large numbers of different antigens are neither practical nor ethical, making large-scale screenings impractical. Fourth, for effective immunotherapy, TAAs need to be expressed in tumor cells of the majority of patients and in the different tumors of the same patients. Cancer cells escape immunotherapy by down-regulating the expression of tumor antigens used for vaccination; it is therefore assumed that proteins that are needed to maintain the transformed state are less likely to be down-regulated by the cancer cells (44, 45, reviewed in Refs. 14, 17, and 37,).
 |
MHC PEPTIDES AS TAAS
|
---|
MHC peptides are potentially very useful TAAs, and some of them were indeed demonstrated to be recognized by circulating cytotoxic T cells and then further tested with laboratory animals and by in vitro, ex vivo, and in human clinical tests (15). Most cancer immunotherapy trials failed to bring about long-lasting cure due to several reasons. In some cases the cause for tumor progression has been shown to be associated with the emergence of resistant tumor cells that either down-regulated the expression of the antigens or reduced the display of the MHC alleles (46, 47). Induction of anergy or apoptosis in the specific T cells was also observed (48). To overcome these obstacles, administration of multiple MHC peptides was attempted, either as mixtures, as parts of mini-genes, as full-size proteins, or even as mRNAs or cDNAs. Vaccination with combinations of MHC class I and class II peptides seemed to be beneficial (49, 50). Dendritic cells turn out to be the most effective antigen-presenting cells for immunotherapy. After loading them with the tumor antigens, they stimulated T cells both ex vivo and in vitro, and when grafted back to the patients they induced anti-tumor immune response, which were sufficiently strong to cause rejection of established tumors more often than the injection of the TAA alone (7, 16, 18, 51).
 |
IDENTIFICATION OF HLA PEPTIDES AS CANCER VACCINE CANDIDATES
|
---|
Identification of MHC peptides of potential value for tumor immunotherapy was approached using different methodologies (reviewed in Refs. 12 and 37). One of the approaches is the genetic approach, based on transfections of expression libraries made from cDNA of tumor cells into cells expressing the desired MHC haplotype. The clones of interest were selected by their ability to elicit immune response in T cells of individuals with the same MHC type. This approach was pioneered by Boon and colleagues and resulted in the identification of TAAs such as the testis antigens MAGE and the melanoma antigens Melan-A/MART and tyrosinase (5258, reviewed in Refs. 5961).
Another approach is the consensus peptide binding motif approach, which is based on identification of sequences that correspond to MHC peptides within the amino acids sequences of known tumor antigens (also known as the epitope deduction or reverse immunology approach). The binding motifs were first established by pooled Edman sequencing of MHC peptides recovered from immunoaffinity-purified specific MHCs (62). The amino acids observed at high levels at particular positions along the peptides were defined as the consensus residues. These were later determined to be the anchor residues of the peptides to the binding pockets in the groove. The motifs were later confirmed and refined by tandem mass spectrometry (MS/MS) sequencing of purified peptides. Dedicated software tools were used to predict the sequence of MHC peptides from amino acid sequences of proteins known to be TAA using the previously established consensus (6372, reviewed in Ref. 73). This was only possible with well-studied MHC haplotypes, such as HLA-A2, that have well-established consensus peptide binding motifs. The predicted peptides were chemically synthesized and tested by reconstitution into empty MHC molecules at the cells surface or into soluble recombinant MHC molecules, followed by testing their stabilization. The peptides were also tested for eliciting T cell responses. Presently, the binding motifs of most MHCs are not sufficiently defined even for the well-studied alleles. Many MHC peptides of tumor antigens such as p53, MAGE, mucin, telomerase, and NY-ESO1 were designed and tested. Some were observed to elicit immune responses in mouse models or in cancer patients (11, 15, 74). However, most of the available programs for predicting MHC class I peptides are successful in predicting only a subset of the peptides, and therefore large numbers of different alternatives need to be tested in peptide binding assays to evaluate their usefulness (75). The T cell-independent approach for identification of MHC peptides is somewhat different from the previous one. It is based on predicting the sequences of MHC peptides based on the sequences of proteins expressed in the cells or tumors. This is followed by purification of peptides from cells and their LC-MS/MS analysis while searching among them for those with the masses and fragmentation patterns similar to those predicted (33).
There are about 105 to 106 MHC-peptide complexes on the surface of each cell, and most of the cellular proteins contain a few different amino acid sequences that fit the binding motifs of known MHCs. Finding which peptides are actually presented on the cells can be done only by direct biochemical analyses. Peptides were recovered from immunoaffinity-purified MHC molecules after detergent extraction of cancer cells. The MHC molecules were denatured and the peptides were separated from the large subunits by ultrafiltration and resolved by reverse-phase high-pressure LC (RP-HPLC) into fractions. The peptides pools in each fraction were tested for their ability to stimulate T cells. The peptides in the active fractions were individually identified by re-fractionations with capillary RP-HPLC combined with electrospray ionization (ESI)-MS/MS. This method, developed by Hunt and colleagues for MHC peptide analysis, serves as the basis for the use of capillary RP-HPLC-ESI-MS/MS in todays proteomics (7679, reviewed in Refs. 8082). Similar to the other approaches, identified peptides of interest were chemically synthesized and tested for T cell responses. The synthetic peptides were tested for their elution time from the capillary columns and MS/MS fragmentation patterns that should be identical to those of the natural peptides, thus indicating the correct assignments of their amino acid sequences. Another advantage of the direct biochemical approach for analysis of MHC peptides is the ability to identify peptides with posttranslational modifications. Peptides modified by deamidation, dimethyl-Arg, phosphorylation, and disulfide-bonded cysteine were identified by this approach (8386, reviewed in Ref. 82).
Because MHC molecules are membrane proteins that are not present in high copy numbers per cell, they are hard to purify in large amounts as needed for peptides analyses. Two other approaches were developed to improve the yields of MHC peptides from a limited number of cancer cells. The first is based on treating cancer cells with mild acid, resulting in partial denaturation of the cell-surface MHC and the release of the bound peptides to the buffer solution, while leaving the majority of the cells intact (87). This way, the cells remain viable, and could be regrown and treated similarly a number of times, each time releasing another aliquot of peptides. Such peptide preparations were largely free of detergents and most of the cellular debris, which facilitated the subsequent analyses by µLC-MS/MS.
Another approach for improved MHC peptide preparations was taken by Hildebrand and colleagues using HLA-B15 (8891) and by us using HLA-A2, -B7, and -Cw4 (92, 93) based on the early experiments of Margulies and colleagues (9499). The approach was based on transfection into cancer cells of expression vectors coding soluble, secreted MHCs lacking a functional transmembrane domain. The cells growth medium was collected multiple times with minimal stress to the cells, and the soluble MHC molecules (sMHC) with their bound peptides were subsequently immunoaffinity purified. With this approach, relatively large amounts of MHC peptides were purified from relatively small numbers of cells. Most cancer cell lines could be transfected with any of the different MHC haplotypes, regardless of their innate MHC haplotypes. The resulting peptide preparations were free of cellular debris or detergents, which simplified the subsequent LC-MS analyses, resulting in the identification of very large numbers of both cancer-related and normal MHC peptides (88, 90, 92, 93). These features make this method amenable for true proteomics-scale analyses of MHC peptides. The identified peptides were searched for those derived from tumor antigens, and some were synthesized and tested for their immunogenic potential. MHC peptide identification by the direct biochemical approach depends on recovery of peptides from cultured cancer cells. This raises the issue whether the peptide repertoire of these cells corresponds to the authentic repertoire of MHC peptides presented on tumor cells. To overcome this, peptides were recovered and identified from patients tumors (3335).
 |
BIOASSAYS: TESTING THE IMMUNOGENICITY OF MHC PEPTIDES
|
---|
After being identified, the MHC peptides of interest should be tested for their potential usefulness as vaccine candidates by evaluating both their binding affinity to the MHC and their immunogenicity before and after vaccination. Usually the available amounts of natural purified peptides are not sufficient for these bioassays. Therefore, subsequent tests are performed with synthetic peptides. First, the peptides are reconstituted into empty MHC molecules, either at the cell surface or as soluble molecules, and tested for their binding affinity to MHC molecules and their stabilization. Empty MHC molecules are available for reconstitution on mutant cell lines, such as RMA-S or T2, which are defective in their peptide loading process. The binding of the peptides and the resulting stabilization of the MHC are followed by fluorescence-activated cell sorter analysis using an anti-native MHC monoclonal antibody such as W6/32 (100). Alternatively, an assembly assay can be performed by adding the peptides to detergent extracts of RMA-S or T2 and following the conformational change in the class I heavy chain and stable association of the heavy chain with ß2-microglobulin (101). The peptides can also be reconstituted into recombinant sMHC and assayed as dimers (102) or tetramers (103).
T cells response to in vitro stimulation or vaccination by peptides presented on antigen-presenting cells or on MHC tetramers is tested by following the synthesis or the secretion by T cells of cytokines, such as interferon
or interleukin-2. The assays include enzyme-linked immunosorbent spot, intercellular cytokine expression, and cytotoxic T cell assays. Immunogenicity can also be tested by delayed-type hypersensitivity or by establishing cytotoxic T cell lines from peripheral blood lymphocytes and following their ability to kill target cells that are presenting the studied peptides. Unfortunately, none of these assays is amenable to high-throughput screening of large numbers of different MHC peptides or of their source proteins (103110, reviewed in Refs. 15 and 111). Testing the immunogenic potential of the MHC peptides is complicated even more by the problem of degeneracy of recognition of multiple peptides by some T cell clones (112). The specificity of T cells to a particular peptide is not always one-to-one. In reality, different peptides can activate one T cell clone. This may limit the use of MHC peptides in the clinic due to concern of inducing autoimmune disease inadvertently (109).
 |
LOOKING AT THE CELLULAR PROTEOME FROM THE POINT OF VIEW OF THE MHC PEPTIDES
|
---|
Now, as large datasets of MHC peptides are being established, they can be used as a new approach for shotgun or comparative proteomics. Indeed, the data obtained by large-scale analyses of MHC peptides points to the source proteins of these peptides. Among these, there are many novel and yet unstudied proteins, many of which were not observed by routine proteomics. A possible explanation is that even though every MHC peptide represents a protein and most cellular proteins contribute one or more peptides to the MHC peptide repertoire, MHC peptides mirror more the patterns of protein degradations rather than the proteome of the cells. The cellular proteome is established by the rate of synthesis of the proteins and by their half-lives in the cells (113, 114). It is conceivable that some slowly synthesized proteins with relatively long half-lives accumulate in cells to a larger extent than other proteins synthesized at a high rate, which are degraded rapidly. MHC peptides are generated only after their proteins of origins have degraded. Therefore, MHC peptides are actually "memories" of past existence of their source proteins. However, once bound to the MHC molecules at the cell surface or on sMHC, the peptides resist degradation for hours. Therefore, it is likely that some relatively abundant MHC peptides originate from proteins that are almost absent from the cells due to their rapid degradation or to incomplete synthesis. It was suggested that significant portions of the proteins synthesized in the cells are rapidly degraded as a normal process in the cell and not only due to errors in their synthesis or improper folding. These proteins, termed "defective ribosome products," are possibly a major source of the MHC peptides repertoire (114117, reviewed in Refs. 118121). This may explain some of the discrepancies between the cellular transcriptome and proteome (113, 122). Moreover, short-lived proteins were demonstrated to be the source of many of the peptides transported by TAP, the transporter associated with antigen processing (123). It was suggested that relatively rapid degradation of some of the newly synthesized proteins allows improved efficiency of protein synthesis by degrading defective ones rather than investing a significant effort in high-fidelity synthesis. Moreover, speeding the response to pathogens by rapidly degrading a fraction of all newly synthesized proteins and displaying the resulting MHC peptides to the T cells confers health benefits that can compensate for the seeming inefficiency of the protein synthesis machinery (114, 119). Studying the cellular proteome by large-scale analyses of the MHC peptides may help to identify such rapidly degrading proteins, some of which may actually be rare proteins that are undetectable by other methods. Among these proteins that did not fold properly or did not join their appropriate functional protein complexes and were subsequently degraded rapidly there may be dysfunctional tumor suppressors and cell cycle regulatory proteins. Such dysfunctional proteins can be identified among the pools of MHC peptides.
A new spin-off from proteomics, called degradomics, is a new research direction aimed at analyzing the cellular proteases and their substrates (124). Because MHC peptides are products of proteolysis, their large-scale analysis offers an insight into the subset of cellular proteases of most interest to immunologists (125). The final size of MHC peptides actually presented at the cell surface reflects the efficiency of proteolysis of the source protein, at the proteasome or elsewhere (126129, reviewed in Refs. 2, 120, 121, and 130132). The presentation of peptides by the MHC molecules serves also as an indication of their transport efficiency into the ER by TAP (123, 133, 134) or by other transporters (135), the efficiency of their amino-peptidase trimming to the final length after binding to the binding groove on the MHC in the ER, and their binding affinity to the MHC molecules (125, 136, 137). Those peptides most effectively processed, transported, and displayed are also better represented among the peptides recovered from cell surface or from soluble MHCs. Such peptides possess some of the desired attributes needed for immunotherapy.
The patterns of cellular MHC peptides change in response to external stimulation not only in accordance with the cellular proteome but also with changes in the proteolytic processing machinery. Stimulation of the immune system due to infections or inflammation leading to elevated cytokines (such as interferon
), induces a transition of the proteasome to the immunoproteasome that contains different catalytic subunits (2, 138141). The immunoproteasome is more active in proteolyzing cellular proteins. It has an altered preference for peptide cleavage sites and is capable of more efficient transport of peptides into the ER (reviewed in Refs. 142 and 143). Therefore, the presentation of specific MHC peptides need to be ascertained separately in healthy cells expressing the normal proteasome and in disease cells expressing the immunoproteasome (140, 144).
The inherent technical difficulties of analyzing MHC peptides make proteomics based on these analyses a more torturous route to take compared with other proteomics approaches based on two-dimensional PAGE or two-dimensional LC. There are close to a thousand different MHC haplotypes in the human population, each possibly displaying a different set of peptides due to the polymorphism of their binding groove (www.ebi.ac.uk/imgt/hla/stats.html). Moreover, in most cases only one MHC peptide is detected from each individual protein. In routine proteomics, proteins are trypsinized and therefore each protein is represented by many peptides, all contributing to its correct identification. Also, in most cases MHC peptides are not preceded or terminated by a particular amino acid (such as Lys or Arg in tryptic peptides). Thus, the numbers of all the possible MHC peptides in the protein databanks are very large. The MS/MS analyses are further complicated due to the fact that many of the MHC peptides are singly charged, often causing their MS/MS spectra to be suboptimal for identification. The molar amounts of MHC peptides are significantly lower than the amounts of proteins obtainable from the same number of cells. Even with the relative high-yield method of purifying peptides from sMHC, there is still a need to grow about 10- to 100-fold more cells to obtain sufficient amount of peptides for MHC peptide identification by µLC-MS/MS than the number of cells needed for identification of the same number of proteins. Moreover, similarly to cellular proteins, MHC peptides are presented at varying copy numbers at the cell surface (also with sMHC), thus complicating the analyses even further (145).
The shortage of dedicated software tools is another limiting factor for large-scale analysis of MHC peptides, even more than for regular proteomics. The available software tools such as Sequest and Mascot are optimized for protein analyses (146150). They combine MS and MS/MS data of a number of different peptides derived from each protein for the identification of the protein. However, MHC peptides analyses calls for the identifications of each of the proteins represented as an MHC peptide separately. Significant computer resources are therefore needed to identify each of the peptides detected in the LC-MS/MS run. Proteomics-scale projects of MHC peptides often include dozens of LC-MS/MS runs, resulting in hundreds of thousands of different MS/MS spectra. To overcome this problem, Beer et al. have developed a new software tool called Pep-Miner to cluster MS/MS data from different LC-MS/MS runs.2 It uses the clustered spectra to identify the peptides in the protein data banks and to compare patterns of MHC peptides between runs. Because every cluster combines many MS/MS spectra of one peptide, it has a better signal-to-noise ratio and a better accuracy than each of the individual MS/MS spectra members of the cluster. We have recently purified and analyzed MHC peptides from the soluble HLA haplotypes (A2, B7, and Cw4) and have observed the presence of a few thousand different MS/MS clusters each possibly representing an MHC peptide. Out of these, a few hundred MHC peptides were identified at high certainty (92, 93).
Databanks containing listings of MHC peptides are available on the internet with software resources for T cell epitope predictions (151, 152). Links to these websites are: syfpeithi.bmi-heidelberg.com/, www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm, and more are listed in MHCligand.ouhsc.edu. The sequences resulting from our large-scale analyses of peptides that were identified by the Pep-Miner software are listed at: www.technion.ac.il/~admon/MHCpeptides.htm. The Pep-Miner software is described at www.haifa.il.ibm.com/projects/verification/bioinformatics/.
 |
FUTURE DIRECTIONS
|
---|
Novel Gene and Open Reading Frame Identifications Based on Sequencing of MHC Peptides
The identification of every MHC peptide indicates the expression of its source protein that can be traced back to its open reading frame (ORF) and gene. This opens the possibility of using the amino acid sequences of identified MHC peptides to identify their coding sequences. It turned out that many of these are expressed from introns, novel ORFs, or genes that were overlooked by other approaches (153157). New DNA sequences of very small ORFs or genes with unusual consensus can be identified this way. Such assignments of new genes and ORFs are likely to be straddled with artifacts due to the immense size of the genome with its six reading frames and the myriad possible alternative splicings, combined with the usual less-than-optimal MS/MS data of MHC peptides. As high-accuracy MS and MS/MS analyses become possible, the confidence of assignments of MHC peptides to DNA sequences will be improved, making such assignments a viable possibility (158160).
The Human MHC Peptide Project
One of the most ambitious proposed research projects concerning MHC peptides involves the determination of the repertoires of all the MHC peptides displayed by the different cell types in the context of the different MHC haplotypes (161). The expected investments and technical obstacles are enormous but the outcome can be very rewarding.
The vast majority of MHC peptides identified so far were from cultured cells rather than from tissues or tumors (the same issue arises with proteomics analyses of culture cells versus cells in their tissues of origin). Which peptides are displayed by cells in body tissues still remains largely unanswered. Acid extractions of MHC peptides from murine tumors were attempted but only a few peptides were identified (162). Immunoaffinity purification of MHC from human tumors, followed by subsequent analyses of the purified MHC peptides, has not been performed as often as with MHC molecules purified from culture cells (33, 34).
Viral and Autoimmune MHC Peptides
MHC peptides can be identified from cells after viral infections, and the identified peptides may serve as new vaccines (163). It is possible to infect cells with viruses and to follow the appearance of MHC peptides derived from the viral proteins. Such vaccines made from peptides or from mini-genes containing the peptides may be safer for use and less expensive to produce and administer than inactivated viruses (111). Autoimmune diseases are often mediated by MHC peptides, and some diseases are linked to specific MHC haplotypes. The MHC peptides that mediate the autoimmune diseases may serve as frameworks for construction of homologous peptides in order to induce anergy in the abnormally activated T cells or loaded on soluble multimers to target the specific disease causing T cell clones. Analysis of MHC peptides presented on particular haplotypes on cells that are targets of the autoimmune T cells may help to identify such disease causing peptides (164).
Personalized Medicine with MHC Peptides
The use of MHC peptides in the clinic as therapeutics for cancer, autoimmunity, or infectious diseases requires a shift to personalized medicine in order to adjust the MHC peptides used as therapeutics to the genetic MHC types of the patients. Because peptide sequences and consensus binding motifs are available for only a small subset of the different MHC haplotypes, only those patients with these haplotypes will be treatable (34, 165, 166). It may become possible to use tumor antigens to vaccinate people at risk of developing specific cancers as immuno-prevention, again matching the peptides to be used for preventive vaccination with the MHC types of the individuals (167).
TCR-like Antibodies May Help to Bypass the Need to Vaccinate
MHC molecules displaying specific peptides on cancer cells can be targeted even if the displayed peptides are not very immunogenic. There are many more known displayed cancer-specific MHC peptides than cancer-specific cell surface proteins. MHC molecules displaying cancer-specific peptides, including those that are not sufficiently immunogenic, are valid targets for recombinant antibodies or recombinant TCRs directed against cell surface MHC-peptide complexes (168174). Such anti-MHC-peptide antibodies (TCR-like antibodies) have been developed and tested for their ability to target cancer cells (175, 176). This opens up a whole new field of targeting cancer cells by recombinant TCRs and TCR-like antibodies. TCR-like antibodies specific for cancer MHC peptides were made as chimeras with the fragment crystallizable parts of the TCR and transfected into already stimulated T cells, providing them with a new anti-cancer specificity (169, 170).
 |
CONCLUSIONS
|
---|
The significance of the analysis of MHC peptides is now well established for development of therapeutics, including new useful tumor vaccines. However, the repertoire of MHC peptides can facilitate the identification of their source proteins, whose rapid degradation is significant to cancer progression and metastasis. Moreover, the identified MHC peptides can help identify new proteins of yet unknown function that are not normally detected by standard proteomics approaches.
 |
FOOTNOTES
|
---|
Received, May 15, 2003, and in revised form, June 23, 2003.
Published, MCP Papers in Press, June 23, 2003, DOI 10.1074/mcp.R300004-MCP200
1 The abbreviations used are: MHC, major histocompatibility complex; sMHC, soluble major histocompatibility complex; HLA, human leukocytes antigen; TCR, T cell receptor; TSA, tumor-specific antigens; TAA, tumor-associated antigens; SEREX, serological identification of antigens by recombinant expression cloning; ER, endoplasmic reticulum; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem mass spectrometry; ORF, open reading frame. 
2 Beer, I., Barnea, E., Ziv, T., and Admon, A., submitted for publication. 
* This work was supported by The Greta Koppel Small Cell Lung Cancer Fund and by the Smoler Proteomics Center at the Technion and by the Israel Ministry of Science. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 
To whom correspondence should be addressed: Department of Biology, TechnionIsrael Institute of Technology, Haifa 32000, Israel. Tel.: 972-4-8293407; Fax: 972-4-8225153; E-mail: admon{at}tx.technion.ac.il
 |
REFERENCES
|
---|
- Kourilsky, P., and Fazilleau, N.
(2001) Self peptides and the peptidic self.
Int. Rev. Immunol.
20, 575
591[Medline]
- Yewdell, J. W., and Bennink, J. R.
(2001) Cut and trim: Generating MHC class I peptide ligands.
Curr. Opin. Immunol.
13, 13
18[CrossRef][Medline]
- Yewdell, J. W.
(2001) Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing.
Trends Cell Biol.
11, 294
297[CrossRef][Medline]
- Davis, S. J., Ikemizu, S., Evans, E. J., Fugger, L., Bakker, T. R., and van der Merwe, P. A.
(2003) The nature of molecular recognition by T cells.
Nat. Immunol.
4, 217
224[CrossRef][Medline]
- Pardoll, D.
(2003) Does the immune system see tumors as foreign or self?
Annu. Rev. Immunol.
21, 807
839[CrossRef][Medline]
- Sprent, J., and Kishimoto, H.
(2002) The thymus and negative selection.
Immunol. Rev.
185, 126
135[CrossRef][Medline]
- Gunzer, M., and Grabbe, S.
(2001) Dendritic cells in cancer immunotherapy.
Crit. Rev. Immunol.
21, 133
145[Medline]
- Pardoll, D. M.
(2000) Therapeutic vaccination for cancer.
Clin. Immunol.
95, S44
S62[CrossRef][Medline]
- Kobayashi, H., Kennedy, R., Lu, J., Davila, E., and Celis, E.
(2000) MHC-binding peptides as immunotherapeutics for cancer.
Immunol. Invest.
29, 105
110[Medline]
- Jager, E., Jager, D., and Knuth, A.
(2000) Peptide vaccination in clinical oncology.
Onkologie
23, 410
415[CrossRef][Medline]
- Rosenberg, S. A.
(2001) Progress in human tumour immunology and immunotherapy.
Nature
411, 380
384[CrossRef][Medline]
- Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G.
(2001) A listing of human tumor antigens recognized by T cells.
Cancer Immunol. Immunother.
50, 3
15[CrossRef][Medline]
- Smyth, M. J., Godfrey, D. I., and Trapani, J. A.
(2001) A fresh look at tumor immunosurveillance and immunotherapy.
Nat. Immunol.
2, 293
299[CrossRef][Medline]
- Buteau, C., Markovic, S. N., and Celis, E.
(2002) Challenges in the development of effective peptide vaccines for cancer.
Mayo Clin. Proc.
77, 339
349[Medline]
- Jager, E., Jager, D., and Knuth, A.
(2002) Clinical cancer vaccine trials.
Curr. Opin. Immunol.
14, 178
182[CrossRef][Medline]
- Machiels, J. P., van Baren, N., and Marchand, M.
(2002) Peptide-based cancer vaccines.
Semin. Oncol.
29, 494
502[CrossRef][Medline]
- Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A.
(2002) Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?
J. Natl. Cancer Inst.
94, 805
818[Abstract/Free Full Text]
- Perez-Diez, A., and Marincola, F. M.
(2002) Immunotherapy against antigenic tumors: A game with a lot of players.
Cell Mol. Life Sci.
59, 230
240[CrossRef][Medline]
- Anderson, G. R., Stoler, D. L., and Brenner, B. M.
(2001) Cancer: The evolved consequence of a destabilized genome.
Bioessays
23, 1037
1046[CrossRef][Medline]
- Reynolds, S. R., Zeleniuch-Jacquotte, A., Shapiro, R. L., Roses, D. F., Harris, M. N., Johnston, D., and Bystryn, J. C.
(2003) Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Clin. Cancer Res.
9, 657
662[Abstract/Free Full Text]
- Vermorken, J. B., Claessen, A. M., van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., Hanna, M. G., Jr., and Pinedo, H. M.
(1999) Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial.
Lancet
353, 345
350[CrossRef][Medline]
- Baars, A., Claessen, A. M., Wagstaff, J., Giaccone, G., Scheper, R. J., Meijer, S., Schakel, M. J., Gall, H. E., Meijer, C. J., Vermorken, J. B., Pinedo, H. M., and van den Eertwegh, A. J.
(2002) A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
Br. J. Cancer
86, 1230
1234[CrossRef][Medline]
- Mocellin, S., Rossi, C. R., Lise, M., and Marincola, F. M.
(2002) Adjuvant immunotherapy for solid tumors: from promise to clinical application.
Cancer Immunol. Immunother.
51, 583
595[CrossRef][Medline]
- Hanash, S., Brichory, F., and Beer, D.
(2001) A proteomic approach to the identification of lung cancer markers.
Dis Markers
17, 295
300[Medline]
- Naour, F. L., Brichory, F., Beretta, L., and Hanash, S. M.
(2002) Identification of tumor-associated antigens using proteomics.
Technol. Cancer Res. Treat.
1, 257
262[Medline]
- Chen, G., Gharib, T. G., Huang, C. C., Thomas, D. G., Shedden, K. A., Taylor, J. M., Kardia, S. L., Misek, D. E., Giordano, T. J., Iannettoni, M. D., Orringer, M. B., Hanash, S. M., and Beer, D. G.
(2002) Proteomic analysis of lung adenocarcinoma: Identification of a highly expressed set of proteins in tumors.
Clin. Cancer Res.
8, 2298
2305[Abstract/Free Full Text]
- Hanash, S.
(2003) Disease proteomics.
Nature
422, 226
232[CrossRef][Medline]
- Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J.
(1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
Proc. Natl. Acad. Sci. U. S. A.
94, 1914
1918[Abstract/Free Full Text]
- Sahin, U., Tureci, O., and Pfreundschuh, M.
(1997) Serological identification of human tumor antigens.
Curr. Opin. Immunol.
9, 709
716[CrossRef][Medline]
- Tureci, O., Sahin, U., and Pfreundschuh, M.
(1997) Serological analysis of human tumor antigens: Molecular definition and implications.
Mol. Med. Today
3, 342
349[CrossRef][Medline]
- Pfreundschuh, M.
(2000) Exploitation of the B cell repertoire for the identification of human tumor antigens.
Cancer Chemother. Pharmacol.
46, S3
S7[Medline]
- Poon, T. C., and Johnson, P. J.
(2001) Proteome analysis and its impact on the discovery of serological tumor markers.
Clin. Chim. Acta
313, 231
239[CrossRef][Medline]
- Schirle, M., Keilholz, W., Weber, B., Gouttefangeas, C., Dumrese, T., Becker, H. D., Stevanovic, S., and Rammensee, H. G.
(2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach.
Eur. J. Immunol.
30, 2216
2225[Medline]
- Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F., Walter, S., Schoor, O., Kurek, R., Loeser, W., Bichler, K. H., Wernet, D., Stevanovic, S., and Rammensee, H. G.
(2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines.
Cancer Res.
62, 5818
5827[Abstract/Free Full Text]
- Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., Rojas, J., Bourdon, A., Bonner, P. L., Wang, L., Christmas, S. E., Travers, P. J., Creaser, C. S., Rees, R. C., and Madrigal, J. A.
(2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Blood
98, 2887
2893[Abstract/Free Full Text]
- Hanash, S. M.
(2001) Global profiling of gene expression in cancer using genomics and proteomics.
Curr. Opin. Mol. Ther.
3, 538
545[Medline]
- Schultze, J. L., and Vonderheide, R. H.
(2001) From cancer genomics to cancer immunotherapy: Toward second-generation tumor antigens.
Trends Immunol.
22, 516
523[CrossRef][Medline]
- Shastri, N., Serwold, T., and Paz, P.
(1998) Reading within the lines: naturally processed peptides displayed by MHC class I molecules.
Curr. Opin. Immunol.
10, 137
144[CrossRef][Medline]
- Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E.
(1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
J. Exp. Med.
184, 465
472[Abstract]
- Nair, S. K., Boczkowski, D., Snyder, D., and Gilboa, E.
(1997) Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
Eur. J. Immunol.
27, 589
597[Medline]
- Nair, S. K., Morse, M., Boczkowski, D., Cumming, R. I., Vasovic, L., Gilboa, E., and Lyerly, H. K.
(2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
Ann. Surg.
235, 540
549[CrossRef][Medline]
- Pardoll, D. M.
(1999) Inducing autoimmune disease to treat cancer.
Proc. Natl. Acad. Sci. U. S. A.
96, 5340
5342[Free Full Text]
- Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., and Zinkernagel, R. M.
(2000) Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease.
J. Exp. Med.
191, 795
804[Abstract/Free Full Text]
- Andersen, M. H., Pedersen, L. O., Capeller, B., Brocker, E. B., Becker, J. C., and thor Straten, P.
(2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Cancer Res.
61, 5964
5968[Abstract/Free Full Text]
- Schmollinger, J. C., Vonderheide, R. H., Hoar, K. M., Maecker, B., Schultze, J. L., Hodi, F. S., Soiffer, R. J., Jung, K., Kuroda, M. J., Letvin, N. L., Greenfield, E. A., Mihm, M., Kutok, J. L., and Dranoff, G.
(2003) Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
Proc. Natl. Acad. Sci. U. S. A.
100, 3398
3403[Abstract/Free Full Text]
- Kaklamanis, L., Gatter, K. C., Hill, A. B., Mortensen, N., Harris, A. L., Krausa, P., McMichael, A., Bodmer, J. G., and Bodmer, W. F.
(1992) Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer.
Int. J. Cancer
51, 379
385[Medline]
- Hicklin, D. J., Marincola, F. M., and Ferrone, S.
(1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
Mol. Med. Today
5, 178
186[CrossRef][Medline]
- Marincola, F. M., Jaffee, E. M., Hicklin, D. J., and Ferrone, S.
(2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
Adv. Immunol.
74, 181
273[Medline]
- Zeng, G., Li, Y., El-Gamil, M., Sidney, J., Sette, A., Wang, R. F., Rosenberg, S. A., and Robbins, P. F.
(2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design.
Cancer Res.
62, 3630
3635[Abstract/Free Full Text]
- Sette, A., Newman, M., Livingston, B., McKinney, D., Sidney, J., Ishioka, G., Tangri, S., Alexander, J., Fikes, J., and Chesnut, R.
(2002) Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.
Tissue Antigens
59, 443
451[CrossRef][Medline]
- Timmerman, J. M., and Levy, R.
(1999) Dendritic cell vaccines for cancer immunotherapy.
Annu. Rev. Med.
50, 507
529[CrossRef][Medline]
- Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T.
(1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
J. Exp. Med.
176, 1453
1457[Abstract]
- Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T.
(1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
J. Exp. Med.
178, 489
495[Abstract]
- Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A.
(1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Proc. Natl. Acad. Sci. U. S. A.
91, 3515
3519[Abstract]
- Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., Renauld, J. C., and Boon, T.
(1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
J. Exp. Med.
180, 35
42[Abstract]
- Boel, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., Boon, T., and van der Bruggen, P.
(1995) BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
Immunity
2, 167
175[Medline]
- Duffour, M. T., Chaux, P., Lurquin, C., Cornelis, G., Boon, T., and van der Bruggen, P.
(1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
Eur. J. Immunol.
29, 3329
3337[CrossRef][Medline]
- Lucas, S., De Plaen, E., and Boon, T.
(2000) MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression.
Int. J. Cancer
87, 55
60[CrossRef][Medline]
- Boon, T., Coulie, P. G., and Van den Eynde, B.
(1997) Tumor antigens recognized by T cells.
Immunol. Today
18, 267
268[CrossRef][Medline]
- Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., and Lucas, S.
(2001) An overview of the MAGE gene family with the identification of all human members of the family.
Cancer Res.
61, 5544
5551[Abstract/Free Full Text]
- Coulie, P. G.
(2002) Cancer immunotherapy with MAGE antigens.
Suppl. Tumori
1, S63
S65[Medline]
- Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G.
(1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.
Nature
351, 290
296[CrossRef][Medline]
- Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanovic, S.
(1999) SYFPEITHI: Database for MHC ligands and peptide motifs.
Immunogenetics
50, 213
219[CrossRef][Medline]
- Mamitsuka, H.
(1998) Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models.
Proteins
33, 460
474[CrossRef][Medline]
- Honeyman, M. C., Brusic, V., Stone, N. L., and Harrison, L. C.
(1998) Neural network-based prediction of candidate T-cell epitopes.
Nat. Biotechnol.
16, 966
969[Medline]
- Lu, J., and Celis, E.
(2000) Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
Cancer Res.
60, 5223
5227[Abstract/Free Full Text]
- Altuvia, Y., Sette, A., Sidney, J., Southwood, S., and Margalit, H.
(1997) A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets.
Hum. Immunol.
58, 1
11[CrossRef][Medline]
- Yu, K., Petrovsky, N., Schonbach, C., Koh, J. Y., and Brusic, V.
(2002) Methods for prediction of peptide binding to MHC molecules: A comparative study.
Mol. Med.
8, 137
148[Medline]
- Reche, P. A., Glutting, J. P., and Reinherz, E. L.
(2002) Prediction of MHC class I binding peptides using profile motifs.
Hum. Immunol.
63, 701
709[CrossRef][Medline]
- Brusic, V., Petrovsky, N., Zhang, G., and Bajic, V. B.
(2002) Prediction of promiscuous peptides that bind HLA class I molecules.
Immunol. Cell Biol.
80, 280
285[CrossRef][Medline]
- Donnes, P., and Elofsson, A.
(2002) Prediction of MHC class I binding peptides, using SVMHC.
BMC Bioinformatics
3, 25[CrossRef][Medline]
- Nussbaum, A. K., Kuttler, C., Hadeler, K. P., Rammensee, H. G., and Schild, H.
(2001) PAProC: A prediction algorithm for proteasomal cleavages available on the WWW.
Immunogenetics
53, 87
94[CrossRef][Medline]
- Nussbaum, A. K., Kuttler, C., Tenzer, S., and Schild, H.
(2003) Using the world wide web for predicting CTL epitopes.
Curr. Opin. Immunol.
15, 69
74[CrossRef][Medline]
- Morris, E. C., Bendle, G. M., and Stauss, H. J.
(2003) Prospects for immunotherapy of malignant disease.
Clin. Exp. Immunol.
131, 1
7[CrossRef][Medline]
- Andersen, M. H., Tan, L., Sondergaard, I., Zeuthen, J., Elliott, T., and Haurum, J. S.
(2000) Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules.
Tissue Antigens
55, 519
531[CrossRef][Medline]
- Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., and Engelhard, V. H.
(1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.
Science
255, 1261
1263[Medline]
- Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F., and Engelhard, V. H.
(1992) HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation.
Science
255, 1264
1266[Medline]
- Henderson, R. A., Cox, A. L., Sakaguchi, K., Appella, E., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H.
(1993) Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells.
Proc. Natl. Acad. Sci. U. S. A.
90, 10275
10279[Abstract]
- Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr.
(1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.
Science
264, 716
719[Medline]
- de Jong, A.
(1998) Contribution of mass spectrometry to contemporary immunology.
Mass Spectrom. Rev.
17, 311
335[CrossRef][Medline]
- Bonner, P. L., Lill, J. R., Hill, S., Creaser, C. S., and Rees, R. C.
(2002) Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells.
J. Immunol. Methods
262, 5
19[CrossRef][Medline]
- Engelhard, V. H., Brickner, A. G., and Zarling, A. L.
(2002) Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire.
Mol. Immunol.
39, 127
137[CrossRef][Medline]
- Meadows, L., Wang, W., den Haan, J. M., Blokland, E., Reinhardus, C., Drijfhout, J. W., Shabanowitz, J., Pierce, R., Agulnik, A. I., Bishop, C. E., Hunt, D. F., Goulmy, E., and Engelhard, V. H.
(1997) The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition.
Immunity
6, 273
281[Medline]
- Skipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V., Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Jr., Boon, T., Hunt, D. F., and Engelhard, V. H.
(1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
J. Exp. Med.
183, 527
534[Abstract]
- Zarling, A. L., Ficarro, S. B., White, F. M., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H.
(2000) Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.
J. Exp. Med.
192, 1755
1762[Abstract/Free Full Text]
- Yague, J., Vazquez, J., and Lopez de Castro, J. A.
(2000) A post-translational modification of nuclear proteins, N(G), N(G)-dimethyl-Arg, found in a natural HLA class I peptide ligand.
Protein Sci.
9, 2210
2217[Abstract]
- Storkus, W. J., Zeh, H. J. d., Salter, R. D., and Lotze, M. T.
(1993) Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution.
J. Immunother.
14, 94
103[Medline]
- Prilliman, K., Lindsey, M., Zuo, Y., Jackson, K. W., Zhang, Y., and Hildebrand, W.
(1997) Large-scale production of class I bound peptides: Assigning a signature to HLA-B*1501.
Immunogenetics
45, 379
385[CrossRef][Medline]
- Prilliman, K. R., Jackson, K. W., Lindsey, M., Wang, J., Crawford, D., and Hildebrand, W. H.
(1999) HLA-B15 peptide ligands are preferentially anchored at their C termini.
J. Immunol.
162, 7277
7284[Abstract/Free Full Text]
- Prilliman, K. R., Lindsey, M., Jackson, K. W., Cole, J., Bonner, R., and Hildebrand, W. H.
(1998) Complexity among constituents of the HLA-B*1501 peptide motif.
Immunogenetics
48, 89
97[CrossRef][Medline]
- Prilliman, K. R., Lindsey, M., Wang, J., Jackson, K. W., and Hildebrand, W. H.
(1999) Peptide motif of the class I molecule HLA-B*1503.
Immunogenetics
49, 144
146[CrossRef][Medline]
- Barnea, E., Beer, I., Patoka, R., Ziv, T., Kessler, O., Tzehoval, E., Eisenbach, L., Zavazava, N., and Admon, A.
(2002) Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens.
Eur. J. Immunol.
32, 213
222[CrossRef][Medline]
- Buchsbaum, S., Barnea, E., Dassau, L., Beer, I., Milner, E., and Admon, A.
(2003) Large-scale analysis of HLA peptides presented by HLA-Cw4.
Immunogenetics
16, 16
- Margulies, D. H., Ramsey, A. L., Boyd, L. F., and McCluskey, J.
(1986) Genetic engineering of an H-2Dd/Q10b chimeric histocompatibility antigen: Purification of soluble protein from transformant cell supernatants.
Proc. Natl. Acad. Sci. U. S. A.
83, 5252
5256[Abstract]
- Schneck, J., Maloy, W. L., Coligan, J. E., and Margulies, D. H.
(1989) Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: Estimation of the affinity of a T cell receptor for MHC.
Cell
56, 47
55[Medline]
- Mage, M. G., Lee, L., Ribaudo, R. K., Corr, M., Kozlowski, S., McHugh, L., and Margulies, D. H.
(1992) A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity.
Proc. Natl. Acad. Sci. U. S. A.
89, 10658
10662[Abstract]
- Kozlowski, S., Takeshita, T., Boehncke, W. H., Takahashi, H., Boyd, L. F., Germain, R. N., Berzofsky, J. A., and Margulies, D. H.
(1991) Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules.
Nature
349, 74
77[CrossRef][Medline]
- DeVito, L. D., Mason, B., Schneck, J., Margulies, D. H., Sollinger, H. W., and Burlingham, W. J.
(1991) Immunochemical analysis of a recombinant, genetically engineered, secreted HLA-A2/Q10b fusion protein.
Hum. Immunol.
32, 125
133[CrossRef][Medline]
- Corr, M., Boyd, L. F., Frankel, S. R., Kozlowski, S., Padlan, E. A., and Margulies, D. H.
(1992) Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: Sequence motif, quantitative binding, and molecular modeling of the complex.
J. Exp. Med.
176, 1681
1692[Abstract]
- Rock, K. L., Rothstein, L., and Benacerraf, B.
(1992) Analysis of the association of peptides of optimal length to class I molecules on the surface of cells.
Proc. Natl. Acad. Sci. U. S. A.
89, 8918
8922[Abstract]
- Elliott, T., Cerundolo, V., Elvin, J., and Townsend, A.
(1991) Peptide-induced conformational change of the class I heavy chain.
Nature
351, 402
406[CrossRef][Medline]
- Abastado, J. P., Lone, Y. C., Casrouge, A., Boulot, G., and Kourilsky, P.
(1995) Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness.
J. Exp. Med.
182, 439
447[Abstract]
- Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M.
(1996) Phenotypic analysis of antigen-specific T lymphocytes.
Science
274, 94
96[Abstract/Free Full Text]
- Schmittel, A., Keilholz, U., and Scheibenbogen, C.
(1997) Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood.
J. Immunol. Methods
210, 167
174[CrossRef][Medline]
- Scheibenbogen, C., Lee, K. H., Mayer, S., Stevanovic, S., Moebius, U., Herr, W., Rammensee, H. G., and Keilholz, U.
(1997) A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.
Clin. Cancer Res.
3, 221
226[Abstract]
- Asai, T., Storkus, W. J., and Whiteside, T. L.
(2000) Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
Clin. Diagn. Lab. Immunol.
7, 145
154[Abstract/Free Full Text]
- Schmittel, A., Keilholz, U., Bauer, S., Kuhne, U., Stevanovic, S., Thiel, E., and Scheibenbogen, C.
(2001) Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins.
J. Immunol. Methods
247, 17
24[CrossRef][Medline]
- Britten, C. M., Meyer, R. G., Kreer, T., Drexler, I., Wolfel, T., and Herr, W.
(2002) The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.
J. Immunol. Methods
259, 95
110[CrossRef][Medline]
- Dutoit, V., Rubio-Godoy, V., Pittet, M. J., Zippelius, A., Dietrich, P. Y., Legal, F. A., Guillaume, P., Romero, P., Cerottini, J. C., Houghten, R. A., Pinilla, C., and Valmori, D.
(2002) Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.
J. Exp. Med.
196, 207
216[Abstract/Free Full Text]
- Whiteside, T. L., Zhao, Y., Tsukishiro, T., Elder, E. M., Gooding, W., and Baar, J.
(2003) Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.
Clin. Cancer Res.
9, 641
649[Abstract/Free Full Text]
- Mashishi, T., and Gray, C. M.
(2002) The ELISPOT assay: An easily transferable method for measuring cellular responses and identifying T cell epitopes.
Clin. Chem. Lab. Med.
40, 903
910[Medline]
- Reiser, J. B., Darnault, C., Gregoire, C., Mosser, T., Mazza, G., Kearney, A., van der Merwe, P. A., Fontecilla-Camps, J. C., Housset, D., and Malissen, B.
(2003) CDR3 loop flexibility contributes to the degeneracy of TCR recognition.
Nat. Immunol.
4, 241
247[CrossRef][Medline]
- Pratt, J. M., Petty, J., Riba-Garcia, I., Robertson, D. H., Gaskell, S. J., Oliver, S. G., and Beynon, R. J.
(2002) Dynamics of protein turnover, a missing dimension in proteomics.
Mol. Cell. Proteomics
1, 579
591[Abstract/Free Full Text]
- Princiotta, M. F., Finzi, D., Qian, S. B., Gibbs, J., Schuchmann, S., Buttgereit, F., Bennink, J. R., and Yewdell, J. W.
(2003) Quantitating protein synthesis, degradation, and endogenous antigen processing.
Immunity
18, 343
354[Medline]
- Yewdell, J. W., Anton, L. C., and Bennink, J. R.
(1996) Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC class I molecules?
J. Immunol.
157, 1823
1826[Abstract]
- Schubert, U., Anton, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., and Bennink, J. R.
(2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.
Nature
404, 770
774[CrossRef][Medline]
- Khan, S., de Giuli, R., Schmidtke, G., Bruns, M., Buchmeier, M., van den Broek, M., and Groettrup, M.
(2001) Cutting edge: Neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein.
J. Immunol.
167, 4801
4804[Abstract/Free Full Text]
- Yewdell, J. W., Schubert, U., and Bennink, J. R.
(2001) At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules.
J. Cell Sci.
114, 845
851[Abstract/Free Full Text]
- Yewdell, J.
(2002) To DRiP or not to DRiP: Generating peptide ligands for MHC class I molecules from biosynthesized proteins.
Mol. Immunol.
39, 139
146[CrossRef][Medline]
- Rock, K. L., York, I. A., Saric, T., and Goldberg, A. L.
(2002) Protein degradation and the generation of MHC class I-presented peptides.
Adv. Immunol.
80, 1
70[Medline]
- Shastri, N., Schwab, S., and Serwold, T.
(2002) Producing natures gene-chips: The generation of peptides for display by MHC class I molecules.
Annu. Rev. Immunol.
20, 463
493[CrossRef][Medline]
- Anderson, L., and Seilhamer, J.
(1997) A comparison of selected mRNA and protein abundances in human liver.
Electrophoresis
18, 533
537[Medline]
- Reits, E. A., Vos, J. C., Gromme, M., and Neefjes, J.
(2000) The major substrates for TAP in vivo are derived from newly synthesized proteins.
Nature
404, 774
778[CrossRef][Medline]
- Lopez-Otin, C., and Overall, C. M.
(2002) Protease degradomics: A new challenge for proteomics.
Nat. Rev. Mol. Cell. Biol.
3, 509
519[CrossRef][Medline]
- Serwold, T., Gonzalez, F., Kim, J., Jacob, R., and Shastri, N.
(2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum.
Nature
419, 480
483[CrossRef][Medline]
- Vinitsky, A., Anton, L. C., Snyder, H. L., Orlowski, M., Bennink, J. R., and Yewdell, J. W.
(1997) The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: Involvement of nonproteasomal cytosolic proteases in antigen processing?
J. Immunol.
159, 554
564[Abstract]
- Luckey, C. J., Marto, J. A., Partridge, M., Hall, E., White, F. M., Lippolis, J. D., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H.
(2001) Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors.
J. Immunol.
167, 1212
1221[Abstract/Free Full Text]
- Luckey, C. J., King, G. M., Marto, J. A., Venketeswaran, S., Maier, B. F., Crotzer, V. L., Colella, T. A., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H.
(1998) Proteasomes can either generate or destroy MHC class I epitopes: Evidence for nonproteasomal epitope generation in the cytosol.
J. Immunol.
161, 112
121[Abstract/Free Full Text]
- Lopez, D., Gil-Torregrosa, B. C., Bergmann, C., and Del Val, M.
(2000) Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
J. Immunol.
164, 5070
5077[Abstract/Free Full Text]
- Kloetzel, P. M.
(2001) Antigen processing by the proteasome.
Nat. Rev. Mol. Cell. Biol.
2, 179
187[CrossRef][Medline]
- Gromme, M., and Neefjes, J.
(2002) Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways.
Mol. Immunol.
39, 181
202[CrossRef][Medline]
- Saveanu, L., Fruci, D., and van Endert, P.
(2002) Beyond the proteasome: Trimming, degradation and generation of MHC class I ligands by auxiliary proteases.
Mol. Immunol.
39, 203
215[CrossRef][Medline]
- Yewdell, J. W., Snyder, H. L., Bacik, I., Anton, L. C., Deng, Y., Behrens, T. W., Bachi, T., and Bennink, J. R.
(1998) TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: Therapeutic potential and insights into TAP-dependent antigen processing.
J. Immunother.
21, 127
131[Medline]
- Cresswell, P., Bangia, N., Dick, T., and Diedrich, G.
(1999) The nature of the MHC class I peptide loading complex.
Immunol. Rev.
172, 21
28[Medline]
- Snyder, H. L., Bacik, I., Bennink, J. R., Kearns, G., Behrens, T. W., Bachi, T., Orlowski, M., and Yewdell, J. W.
(1997) Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing.
J. Exp. Med.
186, 1087
1098[Abstract/Free Full Text]
- Serwold, T., and Shastri, N.
(1999) Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells.
J. Immunol.
162, 4712
4719[Abstract/Free Full Text]
- Serwold, T., Gaw, S., and Shastri, N.
(2001) ER aminopeptidases generate a unique pool of peptides for MHC class I molecules.
Nat. Immunol.
2, 644
651[CrossRef][Medline]
- York, I. A., Goldberg, A. L., Mo, X. Y., and Rock, K. L.
(1999) Proteolysis and class I major histocompatibility complex antigen presentation.
Immunol. Rev.
172, 49
66[Medline]
- Macagno, A., Gilliet, M., Sallusto, F., Lanzavecchia, A., Nestle, F. O., and Groettrup, M.
(1999) Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation.
Eur. J. Immunol.
29, 4037
4042[CrossRef][Medline]
- Morel, S., Levy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A. L., Monsarrat, B., Van Velthoven, R., Cerottini, J. C., Boon, T., Gairin, J. E., and Van den Eynde, B. J.
(2000) Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.
Immunity
12, 107
117[Medline]
- Van den Eynde, B. J., and Morel, S.
(2001) Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome.
Curr. Opin. Immunol.
13, 147
153[CrossRef][Medline]
- Hwang, L. Y., Lieu, P. T., Peterson, P. A., and Yang, Y.
(2001) Functional regulation of immunoproteasomes and transporter associated with antigen processing.
Immunol. Res.
24, 245
272[Medline]
- Toes, R. E., Nussbaum, A. K., Degermann, S., Schirle, M., Emmerich, N. P., Kraft, M., Laplace, C., Zwinderman, A., Dick, T. P., Muller, J., Schonfisch, B., Schmid, C., Fehling, H. J., Stevanovic, S., Rammensee, H. G., and Schild, H.
(2001) Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products.
J. Exp. Med.
194, 1
12[Abstract/Free Full Text]
- Schultz, E. S., Chapiro, J., Lurquin, C., Claverol, S., Burlet-Schiltz, O., Warnier, G., Russo, V., Morel, S., Levy, F., Boon, T., Van den Eynde, B. J., and van der Bruggen, P.
(2002) The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
J. Exp. Med.
195, 391
399[Abstract/Free Full Text]
- Stevanovic, S., and Schild, H.
(1999) Quantitative aspects of T cell activationPeptide generation and editing by MHC class I molecules.
Semin. Immunol.
11, 375
384[CrossRef][Medline]
- Eng, J., McCormack, A., and Yates, J.
(1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database.
J. Am. Soc. Mass. Spect.
5, 976
989[CrossRef]
- Mann, M., and Wilm, M.
(1994) Error-tolerant identification of peptides in sequence databases by peptide sequence tags.
Anal. Chem.
66, 4390
4399[Medline]
- Yates, J. R., 3rd, Eng, J. K., McCormack, A. L., and Schieltz, D.
(1995) Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database.
Anal. Chem.
67, 1426
1436[Medline]
- Eriksson, J., Chait, B. T., and Fenyo, D.
(2000) A statistical basis for testing the significance of mass spectrometric protein identification results.
Anal. Chem.
72, 999
1005[CrossRef][Medline]
- Boguski, M. S., and McIntosh, M. W.
(2003) Biomedical informatics for proteomics.
Nature
422, 233
237[CrossRef][Medline]
- Brusic, V., Zeleznikow, J., and Petrovsky, N.
(2000) Molecular immunology databases and data repositories.
J. Immunol. Methods
238, 17
28[CrossRef][Medline]
- Sathiamurthy, M., Hickman, H. D., Cavett, J. W., Zahoor, A., Prilliman, K., Metcalf, S., Fernandez Vina, M., and Hildebrand, W. H.
(2003) Population of the HLA ligand database.
Tissue Antigens
61, 12
19[CrossRef][Medline]
- Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T.
(1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.
Proc. Natl. Acad. Sci. U. S. A.
92, 7976
7980[Abstract]
- Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethe, B., Jotereau, F., and Boon, T.
(1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.
J. Exp. Med.
183, 1173
1183[Abstract]
- Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., and Traversari, C.
(1998) Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
J. Exp. Med.
188, 1005
1016[Abstract/Free Full Text]
- Van Den Eynde, B. J., Gaugler, B., Probst-Kepper, M., Michaux, L., Devuyst, O., Lorge, F., Weynants, P., and Boon, T.
(1999) A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription.
J. Exp. Med.
190, 1793
1800[Abstract/Free Full Text]
- Malarkannan, S., Horng, T., Shih, P. P., Schwab, S., and Shastri, N.
(1999) Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism.
Immunity
10, 681
690[Medline]
- Choudhary, J. S., Blackstock, W. P., Creasy, D. M., and Cottrell, J. S.
(2001) Interrogating the human genome using uninterpreted mass spectrometry data.
Proteomics
1, 651
667[CrossRef][Medline]
- Choudhary, J. S., Blackstock, W. P., Creasy, D. M., and Cottrell, J. S.
(2001) Matching peptide mass spectra to EST and genomic DNA databases.
Trends Biotechnol.
19, S17
S22[CrossRef][Medline]
- Altuvia, Y., Lithwick, G., and Margalit, H.
(2001) Harnessing the cellular immune system to the gene-prediction cart.
Trends Genet.
17, 732
734[CrossRef][Medline]
- Buus, S.
(1999) Description and prediction of peptide-MHC binding: The "human MHC project".
Curr. Opin. Immunol.
11, 209
213[CrossRef][Medline]
- Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and Eisenbach, L.
(1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma.
Nature
369, 67
71[Medline]
- Yewdell, J., Anton, L. C., Bacik, I., Schubert, U., Snyder, H. L., and Bennink, J. R.
(1999) Generating MHC class I ligands from viral gene products.
Immunol. Rev.
172, 97
108[Medline]
- Nepom, G. T., Lippolis, J. D., White, F. M., Masewicz, S., Marto, J. A., Herman, A., Luckey, C. J., Falk, B., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., and Nepom, B. S.
(2001) Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65).
Proc. Natl. Acad. Sci. U. S. A.
98, 1763
1768[Abstract/Free Full Text]
- Rammensee, H. G., Weinschenk, T., Gouttefangeas, C., and Stevanovi Eq, S.
(2002) Towards patient-specific tumor antigen selection for vac-cination.
Immunol. Rev.
188, 164
176[CrossRef][Medline]
- Nadler, L. M., and Schultze, J. L.
(2002) From genomics to cancer vaccines: Patient-tailored or universal vaccines?
Curr. Opin. Mol. Ther.
4, 572
576[Medline]
- Lollini, P. L., and Forni, G.
(2003) Cancer immunoprevention: Tracking down persistent tumor antigens.
Trends Immunol.
24, 62
66[CrossRef][Medline]
- Eshhar, Z.
(1997) Tumor-specific T-bodies: Towards clinical application.
Cancer Immunol. Immunother.
45, 131
136[CrossRef][Medline]
- Chames, P., Hufton, S. E., Coulie, P. G., Uchanska-Ziegler, B., and Hoogenboom, H. R.
(2000) Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.
Proc. Natl. Acad. Sci. U. S. A.
97, 7969
7974[Abstract/Free Full Text]
- Chames, P., Willemsen, R. A., Rojas, G., Dieckmann, D., Rem, L., Schuler, G., Bolhuis, R. L., and Hoogenboom, H. R.
(2002) TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.
J. Immunol.
169, 1110
1118[Abstract/Free Full Text]
- Willemsen, R. A., Weijtens, M. E., Ronteltap, C., Eshhar, Z., Gratama, J. W., Chames, P., and Bolhuis, R. L.
(2000) Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.
Gene Ther.
7, 1369
1377[CrossRef][Medline]
- Denkberg, G., Cohen, C. J., Lev, A., Chames, P., Hoogenboom, H. R., and Reiter, Y.
(2002) Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity.
Proc. Natl. Acad. Sci. U. S. A.
99, 9421
9426[Abstract/Free Full Text]
- Willemsen, R. A., Debets, R., Hart, E., Hoogenboom, H. R., Bolhuis, R. L., and Chames, P.
(2001) A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.
Gene Ther.
8, 1601
1608[CrossRef][Medline]
- Willemsen, R. A., Debets, R., Chames, P., and Bolhuis, R. L.
(2003) Genetic engineering of T cell specificity for immunotherapy of cancer.
Hum. Immunol.
64, 56
68[CrossRef][Medline]
- Cohen, C. J., Hoffmann, N., Farago, M., Hoogenboom, H. R., Eisenbach, L., and Reiter, Y.
(2002) Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cancer Res.
62, 5835
5844[Abstract/Free Full Text]
- Lev, A., Denkberg, G., Cohen, C. J., Tzukerman, M., Skorecki, K. L., Chames, P., Hoogenboom, H. R., and Reiter, Y.
(2002) Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Cancer Res.
62, 3184
3194[Abstract/Free Full Text]